Furthermore, one of the more recent studies was a HER2-positive breast cancer phase I study to evaluate the biodistribution, radiation dosimetry, tumor imaging ability, and safety of I-131 radionuclide theranostic agents targeting cancers expressing HER2 [21]. The gene discussed is ERBB2; the disease is neoplasm.